Work

Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study.

Year: 2013

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-13-b187

Authors: Joaquin Mateo, Patrick Schoffski, David Olmos, Herlinde Dumez, Victor Moreno, Fei Jie, Srinivasu Poondru, Nancy L. Samberg, Jan M. Van Tornout, Stanley B. Kaye, Patricia M. LoRusso

Institutions: Institute of Cancer Research, Universitair Ziekenhuis Leuven, Astellas Pharma (United States), The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2090998516

Cites:

Cited by: 1

Related to: 10